What is the therapeutic dose of enoxaparin (Lovenox) for an adult, and how should the dose be adjusted for renal impairment or obesity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Therapeutic Enoxaparin Dosing

The standard therapeutic dose of enoxaparin is 1 mg/kg subcutaneously every 12 hours for patients with normal renal function (CrCl ≥30 mL/min), with mandatory dose reduction to 1 mg/kg once daily for severe renal impairment (CrCl <30 mL/min). 1, 2

Standard Dosing Algorithm

For Acute Coronary Syndromes (ACS)

Initial therapy:

  • 1 mg/kg subcutaneously every 12 hours for patients with normal renal function 1, 2
  • Continue for duration of hospitalization or up to 8 days 3

Age-specific modifications for STEMI with fibrinolysis:

  • Age <75 years: 30 mg IV bolus, then 1 mg/kg SC every 12 hours (maximum 100 mg for first 2 doses) 1, 2
  • Age ≥75 years: No IV bolus, 0.75 mg/kg SC every 12 hours (maximum 75 mg for first 2 doses) 1, 2, 4

For Venous Thromboembolism (VTE)

Standard treatment dose:

  • 1 mg/kg subcutaneously every 12 hours OR
  • 1.5 mg/kg subcutaneously once daily 5

Both regimens are FDA-approved and equally effective for VTE treatment 3.

Renal Impairment Adjustments

This is the most critical adjustment and must not be missed:

  • CrCl ≥30 mL/min: Standard dosing (1 mg/kg every 12 hours)
  • CrCl <30 mL/min: Reduce to 1 mg/kg once daily (every 24 hours) 1, 2, 6, 4, 6

The 2025 ACC/AHA guidelines explicitly state this dose reduction is mandatory regardless of indication 1, 2. Enoxaparin clearance decreases by 31% with moderate renal impairment (CrCl 30-60 mL/min) and 44% with severe impairment (CrCl <30 mL/min), leading to 2-3 fold increased bleeding risk without adjustment 6, 7.

Important caveat: Some evidence suggests dose reduction may be warranted even for CrCl 30-50 mL/min, particularly with prolonged therapy (>10 days) 7, 8. Consider using 0.8 mg/kg every 12 hours for moderate impairment (CrCl 30-50 mL/min) based on pharmacokinetic data 7.

Calculate CrCl using Cockcroft-Gault equation (not eGFR), as this was used in clinical trials 8.

Obesity Adjustments

Contrary to common practice, do NOT routinely reduce doses or cap doses in obesity.

  • Use actual body weight for dosing up to very high weights 9, 10, 11, 12
  • Standard 1 mg/kg dosing in obesity often results in supratherapeutic levels and increased bleeding 10, 12

For severe obesity (BMI ≥40 kg/m² or weight >140 kg):

  • Consider dose reduction to 0.75-0.85 mg/kg every 12 hours 10, 12
  • This reduced range achieves therapeutic anti-Xa levels in 62-66% of patients versus only 42% with standard dosing 10, 12
  • 85% of bleeding events in obese patients occurred with doses ≥0.95 mg/kg 10

Alternative approach for extreme obesity:

  • Use IBW + 40% of excess weight or LBW + 40% as dosing weight 11
  • This provides better correlation with therapeutic anti-Xa levels than actual body weight in BMI ≥30 kg/m² 11

Do not "dose cap" at arbitrary weights (e.g., 100 kg maximum dose) as this leads to subtherapeutic dosing and thrombotic risk 12.

Special Populations

Low Body Weight (<50 kg)

  • Limited data, but consider dose reduction to 30 mg every 12 hours for prophylactic dosing 13
  • For therapeutic dosing, use standard weight-based calculation but monitor closely
  • Bleeding risk may be increased with standard dosing 13

Monitoring Considerations

Anti-Xa monitoring is NOT routinely required but should be considered in:

  • Severe renal impairment (CrCl <30 mL/min) on prolonged therapy 6, 14
  • Extreme obesity (weight >190 kg or BMI ≥40 kg/m²) 10, 12, 8
  • Pregnancy (not covered in provided evidence)
  • Therapeutic failure or bleeding complications

Target therapeutic anti-Xa range: 0.5-1.0 IU/mL (or 0.5-1.2 IU/mL per some sources) 7

  • Draw 4 hours post-dose for twice-daily dosing 6
  • Draw after 3-4 doses to reach steady state 6

Additional Risk Factors for Supratherapeutic Levels

Beyond renal impairment and obesity, female sex, lower BMI, concomitant corticosteroids, and multiple doses increase risk of supratherapeutic anti-Xa levels 15. Consider empiric dose reduction or earlier monitoring in patients with multiple risk factors.

Critical Safety Points

Never switch between enoxaparin and unfractionated heparin during treatment - this significantly increases bleeding risk 4.

For PCI procedures in patients already on enoxaparin:

  • If last dose <8 hours ago: No additional dosing needed
  • If last dose 8-12 hours ago: Give 0.3 mg/kg IV bolus
  • If no prior enoxaparin: Give 0.5-0.75 mg/kg IV bolus 1, 2

The most common dosing error is failure to adjust for severe renal impairment, which substantially increases bleeding risk without improving efficacy 6, 7.

References

Guideline

cancer-associated venous thromboembolic disease, version 2.2024, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2024

Guideline

venous thromboembolic disease.

Journal of the National Comprehensive Cancer Network : JNCCN, 2013

Research

A systematic review of therapeutic enoxaparin dosing in obesity.

Journal of thrombosis and thrombolysis, 2024

Research

Determination of the optimal obesity-adjusted dosing weight for enoxaparin.

British journal of clinical pharmacology, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.